{"protocolSection": {"identificationModule": {"nctId": "NCT01706198", "orgStudyIdInfo": {"id": "115150"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma", "officialTitle": "A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma"}, "statusModule": {"statusVerifiedDate": "2018-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-11-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-12-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-12-16", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-10-04", "studyFirstSubmitQcDate": "2012-10-11", "studyFirstPostDateStruct": {"date": "2012-10-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-12-06", "resultsFirstSubmitQcDate": "2018-07-26", "resultsFirstPostDateStruct": {"date": "2019-01-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-07-26", "lastUpdatePostDateStruct": {"date": "2019-01-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) ) delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing asthma maintenance therapy over twelve months in subjects diagnosed with asthma. This is a Phase III multi-centre, randomised open label study. Subjects who meet the eligibility criteria are randomised and will enter a 12 month treatment period.", "detailedDescription": "This is a Phase III multi-centre, randomised open label study performed in subjects followed in primary care who have a diagnosis of and receive regular treatment for asthma in a localised geographical region of the UK"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["respiratory", "adult", "asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 4233, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "FF/VI", "type": "EXPERIMENTAL", "description": "fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler", "interventionNames": ["Drug: fluticasone furoate + vilanterol", "Drug: inhaled corticosteroid with or without a long acting beta2-agonist"]}, {"label": "ICS or ICS/LABA maintenance therapy", "type": "ACTIVE_COMPARATOR", "description": "inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)", "interventionNames": ["Drug: inhaled corticosteroid with or without a long acting beta2-agonist"]}], "interventions": [{"type": "DRUG", "name": "fluticasone furoate + vilanterol", "description": "once daily via a Novel Dry Powder Inhaler", "armGroupLabels": ["FF/VI"]}, {"type": "DRUG", "name": "inhaled corticosteroid with or without a long acting beta2-agonist", "description": "ICS alone or in combination with a long acting bronchodilator", "armGroupLabels": ["FF/VI", "ICS or ICS/LABA maintenance therapy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The primary efficacy analysis (PEA) Population is defined as all Intent-to-Treat (ITT) participants (that is, all participants who were randomized and received at least one prescription of study medication) who have an ACT total score of \\<20 at Baseline (Day 0). The percentage of responders that is participants with an ACT total score \\>=20 or an increase from Baseline of \\>=3 has been presented", "timeFrame": "Baseline (Day 0) and Week 24"}], "secondaryOutcomes": [{"measure": "Percentage of Participants Who Have Either an ACT Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. ITT Population comprised of all participants who were randomized and received at least one prescription of study medication. The percentage of responders that is participants with an ACT total score \\>=20 or an increase from Baseline of \\>=3 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "timeFrame": "Baseline (Day 0) and Weeks 12, 40 and 52"}, {"measure": "Percentage of Participants With Asthma Control (ACT Total Score >=20) at Weeks 12, 24, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants with an ACT total score \\>=20 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "timeFrame": "Weeks 12, 24, 40 and 52"}, {"measure": "Percentage of Participants Who Have an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 24, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants with an increase in ACT total score \\>=3 from Baseline has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "timeFrame": "Baseline (Day 0) and Weeks 12, 24, 40 and 52"}, {"measure": "Mean Change From Baseline in ACT Total Score at Weeks 12, 24, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. Baseline value is the value at Visit 2 (Day 0) assessment. Change from Baseline is the value at post-dose visit minus Baseline. The least square mean change in ACT scores has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "timeFrame": "Baseline (Day 0) and Weeks 12, 24, 40 and 52"}, {"measure": "Percentage of Participants in Each ACT Total Score Category (>=20, 16 to 19, <=15) at Weeks 12, 24, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants under each ACT total score category that is \\>=20, 16 to 19 and \\<=15 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "timeFrame": "Weeks 12, 24, 40 and 52"}, {"measure": "Annual Rate of Asthma-related Secondary Care Contacts", "description": "All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the National Health Service (NHS) as identified in the electronic medical records (EMR). Contacts were defined to be asthma-related if the most prominent signs and symptoms that the participant presented were a direct result of the participant's asthma. An asthma-related secondary care contact is defined as an inpatient admission or a specialist outpatient visit or an accident and emergency (A\\&E) contact. A participant with an A\\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. The least square mean annual rate of all asthma-related secondary care contacts along with 95% confidence interval has been presented.", "timeFrame": "Up to Week 52"}, {"measure": "Annual Rate of Asthma-related Primary Care Contacts", "description": "All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the NHS as identified in the EMR. Contacts were defined to be asthma-related if the most prominent signs and symptoms that the participant presented were a direct result of the participant's asthma. Asthma-related primary care contacts is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional that can be considered as asthma-related as per Read codes. The least square mean annual rate of all asthma-related primary care contacts along with 95% confidence interval has been presented.", "timeFrame": "Up to Week 52"}, {"measure": "Number of Participants With Time to First Asthma-related Primary Care Contact", "description": "Asthma-related primary care contact is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional that can be considered as asthma-related as per Read codes. Time to first asthma-related primary care contact was measured from the date of randomization (that is, study treatment start date) to the date of first asthma-related primary care contact, or study treatment stop date for participants who completed the study without any asthma-related primary care contacts (censored). Analyses of time to first asthma-related primary care contact was censored at Day 364. The number of participants at risk at Weeks 0, 13, 26, 39 and 52 has been presented. Kaplan Meier method of analysis was used. Study related primary care contacts (that is, contacts scheduled solely due to the participant taking part in clinical trial) were excluded from this analysis.", "timeFrame": "Up to Week 52"}, {"measure": "Annual Rate of All On-treatment Secondary Care Contacts", "description": "A secondary care contact is defined as an inpatient admission or a specialist outpatient visit or an A\\&E contact. A participant with an A\\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. The inpatient admissions recorded at two hospitals on the same day, were counted as a single (inpatient admission) secondary care contact. In the situation where inpatient admission periods overlapped (example, a new inpatient admission was recorded within the dates of an existing inpatient admission period), it was counted as a single (inpatient admission) healthcare contact with start date defined as the earliest inpatient admission date for either of the overlapping admissions and end date defined as the latest discharge date for either of the overlapping admissions. The least square mean annual rate of all on-treatment secondary care contacts along with 95% confidence interval has been summarized.", "timeFrame": "Up to Week 52"}, {"measure": "Annual Rate of All On-treatment Primary Care Contacts", "description": "All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the NHS as identified in the EMR. Total primary care contacts is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional. The least square mean annual rate of all on-treatment primary care contacts along with 95% confidence interval has been presented.", "timeFrame": "Up to Week 52"}, {"measure": "Number of Participants With Time to First Primary Care Contact", "description": "Time to first primary care contact is measured from the date of randomization (that is, study treatment start date) to the date of first primary care contact, or study treatment stop date for participants who completed the study without any primary care contacts (censored). Analyses of time to first primary care contact will be censored at Day 364. The number of participants at risk at Weeks 0, 13, 26, 39 and 52 has been presented. Kaplan Meier method of analysis was used. Study related primary care contacts (that is, contacts scheduled solely due to the participant taking part in clinical trial) were excluded from this analysis.", "timeFrame": "Up to Week 52"}, {"measure": "Mean Annual Rate of Severe Asthma Exacerbations", "description": "A severe asthma exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) or antibiotics, and inpatient hospitalization, or emergency department visit due to asthma that required systemic corticosteroids or antibiotics. Least square mean for annual rate of severe asthma exacerbation along with 95% confidence interval has been presented.", "timeFrame": "Up to Week 52"}, {"measure": "Time to First Severe Asthma Exacerbation.", "description": "A severe asthma exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) or antibiotics, and inpatient hospitalization, or emergency department visit due to asthma that required systemic corticosteroids or antibiotics. The date of a severe asthma exacerbation was defined as the exacerbation onset date. Participants who completed the study without a severe asthma exacerbation were censored. Time to first severe asthma exacerbation was measured from the date of randomization (that is, study treatment start date) to the onset date of first severe asthma exacerbation, or study treatment stop date for participants who completed the study without any severe asthma exacerbations (censored). Analyses of time to first severe asthma exacerbation was censored at Day 364. The number of participants with severe asthma exacerbation has been presented.", "timeFrame": "Up to Week 52"}, {"measure": "Mean Number of Salbutamol Inhalers Prescribed for Each Participant Over the 12 Month Treatment Period.", "description": "Salbutamol was prescribed as a rescue medication to be used as and when necessary throughout the study. The number of salbutamol inhalers used by each participant during the study was calculated based on the total number of inhalers (adjusted to an equivalence of 200 metered actuations) prescribed. Number of salbutamol inhalers prescribed during the study was derived taking the participants time on study medication into account so it corresponds to 12 months on treatment. The least square mean number of salbutamol inhalers prescribed per participant during the study has been presented. Only participants exposed to study drug for at least 30 days were included in the analysis.", "timeFrame": "Up to 12 months"}, {"measure": "Time to Modification of Initial Therapy", "description": "Initial therapy is defined as the treatment that the participant was prescribed at randomization. Modification of initial therapy included any change in brand, dose or frequency of inhaler, that is, stepping up in class, dose or frequency, stepping down in class, dose or frequency, switching to another brand of inhaler, switching treatment arm or withdrawal from the study. Time to modification of initial therapy was measured from the date of randomization (that is, exposure start date) to the date of modification of initial therapy or date of treatment termination for participants who completed the study without modifiying initial therapy (censored). The number of participants with modification of initial therapy has been presented.", "timeFrame": "Up to Week 52"}, {"measure": "Percentage of Participants Who Have an Increase From Baseline of >=0.5 in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] Total Score at Week 52.", "description": "The AQLQ(S) contained 32 items under the following four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items) and environmental stimuli (4 items). The response format consisted of a seven-point scale where a value of 1 indicated \"total impairment\" and a value of 7 indicated \"no impairment\". The total AQLQ(S) score is the mean of all 32 items in the questionnaire and each individual domain score was calculated as the mean of the items within that domain. Hence, the total and domain scores were each defined on a range from 1 to 7 with higher scores indicating a higher quality of life. Baseline value is the value at Day 0 assessment. Change from Baseline is post dose visit value minus Baseline. The percentage of responders that is, participants with an increase from Baseline of \\>=0.5 in AQLQ(S) total score has been presented. Only those participants available at the specified time point was analyzed.", "timeFrame": "Baseline (Day 0) and Week 52"}, {"measure": "Percentage of Participants Who Have an Increase From Baseline of >=0.5 in AQLQ(S) Environmental Stimuli Domain Score at Week 52.", "description": "The AQLQ(S) contained 32 items under the following four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items) and environmental stimuli (4 items). The response format consisted of a seven-point scale where a value of 1 indicated \"total impairment\" and a value of 7 indicated \"no impairment\". The total environmental stimuli domain score was calculated as the mean of the items within the environmental stimuli domain. Hence, the environmental stimuli domain scores were each defined on a range from 1 to 7 with higher scores indicating a higher quality of life. Baseline value is the value at Day 0 assessment. Change from Baseline is post dose visit value minus Baseline. The percentage of responders that is, participants with an increase from Baseline of \\>=0.5 in AQLQ(S) environmental stimuli domain score has been presented. Only those participants available at the specified time point was analyzed.", "timeFrame": "Baseline (Day 0) and Week 52"}, {"measure": "Percentage of Participants With Serious Adverse Event (SAE) of Pneumonia", "description": "A serious advent event (SAE) of pneumonia was defined as any SAE in the adverse event special interest (AESI) group of \"pneumonia\". The incidence of the SAEs of pneumonia for each treatment group is defined as the percentage of participants in that group who have experienced at least one SAE of pneumonia from start date of study treatment to the stop date of exposure + 28 days or date of study discontinuation, whichever is earliest. The percentage of participants with SAE of pneumonia has been presented.", "timeFrame": "Up to Week 52"}, {"measure": "Time to First SAE of Pneumonia", "description": "An SAE of pneumonia was defined as any SAE in the AESI group of \"pneumonia\". The date of an event for an SAE of pneumonia was the AE onset date. Participants who do not have an SAE of pneumonia during the first 364 days of the treatment period (start date of exposure to min \\[end date of exposure + 28 days, date of study discontinuation, start date of exposure + 363\\]) were censored. Time to first SAE of pneumonia was measured from the date of randomization (that is, study treatment start date) to the onset date of first SAE of pneumonia. The number of participants with first on-treatment SAE of pneumonia has been presented.", "timeFrame": "Up to Week 52"}, {"measure": "Number of Participants With Fatal SAEs of Pneumonia", "description": "All SAEs included in the AESI group of \"pneumonia\" were considered as an SAE of pneumonia. Fatal SAEs of pneumonia are SAEs that led to death of participants. The number of participants with fatal SAEs of pneumonia has been presented.", "timeFrame": "Up to Week 52"}, {"measure": "Number of Participants With SAEs", "description": "An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events which may require medical or surgical intervention for example, invasive or malignant cancers; all events of possible drug-induced liver injury with hyperbilirubinemia. The number of participants with on-treatment SAEs has been summarized.", "timeFrame": "Up to Week 52"}, {"measure": "Number of Participants With Adverse Drug Reactions (ADRs)", "description": "An ADR is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. ADRs are a subset of AEs for a given medicinal product.", "timeFrame": "Up to Week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nSubjects eligible for enrolment in the study must meet all of the following criteria:\n\n1. Informed consent: Subjects must be able to provide informed consent, have their consent signed and dated.\n2. Type of subject: Subjects with documented GP diagnosis of asthma as their primary respiratory disease.\n3. Current Anti-Asthma Therapy: All subjects must be prescribed maintenance therapy and receiving ICS with or without LABA (either a fixed combination or via separate inhalers), and for at least 4 weeks prior to Visit 2.\n\n   * Other background asthma medication such as anti-leukotrienes are permitted\n4. All subjects on ICS monotherapy or ICS/LABA combination (this can be a fixed dose combination or an ICS alone or LABA alone in separate inhalers) must have had symptoms in the past week prior to Visit 2. Symptoms are defined by daytime symptoms more than twice per week, use of short-acting beta2-agonist bronchodilator more than twice per week, any limitation of activities, or any nocturnal symptoms/awakening. (The symptoms are based on subject's recall and are consistent with the GINA and in principal with the BTS/SIGN guidelines).\n5. Subject questionnaires: Subjects must be able to complete the electronic subject questionnaires as well as those questionnaires that are completed by phone or provide a proxy e.g. a partner/relative/a friend who can do so on their behalf\n6. Gender and Age: Male or female subjects aged \u226518 years of age at Visit 1. A female is eligible to enter and participate in the study if she is of:\n\n   * Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile). Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age appropriate, history of vasomotor symptoms. However in questionable cases, a blood sample with FSH \\> 40MIU/ml and estradiol \\<40pg/ml (\\<147 pmol/L) is confirmatory.\n\nOR Child bearing potential has a negative urine pregnancy test at Visit 2, and agrees to one of the highly effective and acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - Visit 2 to the end of the study).\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria must not be enrolled in the study:\n\n1. Recent history of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within the last 6 months.\n2. COPD Respiratory Disease: A subject must not have current evidence or GP diagnosis of chronic obstructive pulmonary disease.\n3. Other diseases/abnormalities: Subjects with historical or current evidence of uncontrolled or clinically significant disease. Significant is defined as any disease that, in the opinion of the GP/ Investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.\n4. Drug/food allergy: Subjects with a history of hypersensitivity to any of the study medications (e.g., beta2-agonists, corticosteroid) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the GP/ Investigator, contraindicates the subject's participation will also be excluded.\n5. Investigational Medications: A subject must not have used any investigational drug within 30 days prior to Visit 2 or within five half-lives (t\u00bd) of the prior investigational study (whichever is longer of the two), (if unsure discuss with the medical monitor prior to screening)\n6. Chronic user of systemic corticosteroids: A subject who, in the opinion of the GP/Investigator, is considered to be a chronic user of systemic corticosteroids for respiratory or other indications (if unsure discuss with the medical monitor prior to screening)\n7. Subjects who are using LABA without an ICS as asthma maintenance therapy.\n8. Subjects who plan to move away from the geographical area where the study is being conducted during the study period and/or if subjects have not consented to their medical records being part of the electronic medical records database that is operational in the Salford area.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Altrincham", "state": "Cheshire", "zip": "WA14 2NW", "country": "United Kingdom", "geoPoint": {"lat": 53.38752, "lon": -2.34848}}, {"facility": "GSK Investigational Site", "city": "Altrincham", "state": "Cheshire", "zip": "WA14 5ET", "country": "United Kingdom", "geoPoint": {"lat": 53.38752, "lon": -2.34848}}, {"facility": "GSK Investigational Site", "city": "Altrincham", "state": "Cheshire", "zip": "WA14 5GR", "country": "United Kingdom", "geoPoint": {"lat": 53.38752, "lon": -2.34848}}, {"facility": "GSK Investigational Site", "city": "Altrincham", "state": "Cheshire", "zip": "WA14 5NH", "country": "United Kingdom", "geoPoint": {"lat": 53.38752, "lon": -2.34848}}, {"facility": "GSK Investigational Site", "city": "Altrincham", "state": "Cheshire", "zip": "WA14 5PF", "country": "United Kingdom", "geoPoint": {"lat": 53.38752, "lon": -2.34848}}, {"facility": "GSK Investigational Site", "city": "Bowdon", "state": "Cheshire", "zip": "WA14 3BD", "country": "United Kingdom", "geoPoint": {"lat": 53.37644, "lon": -2.36532}}, {"facility": "GSK Investigational Site", "city": "Cheadle Hulme", "state": "Cheshire", "zip": "SK8 5EG", "country": "United Kingdom", "geoPoint": {"lat": 53.3761, "lon": -2.1897}}, {"facility": "GSK Investigational Site", "city": "Cheadle", "state": "Cheshire", "zip": "SK8 6LQ", "country": "United Kingdom", "geoPoint": {"lat": 52.98333, "lon": -1.98333}}, {"facility": "GSK Investigational Site", "city": "Edgeley", "state": "Cheshire", "zip": "SK3 9LQ", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Gatley", "state": "Cheshire", "zip": "SK84NG", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Heald Green", "state": "Cheshire", "zip": "SK8 3QA", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Sale", "state": "Cheshire", "zip": "M33 2RH", "country": "United Kingdom", "geoPoint": {"lat": 53.42519, "lon": -2.32443}}, {"facility": "GSK Investigational Site", "city": "Sale", "state": "Cheshire", "zip": "M33 2UP", "country": "United Kingdom", "geoPoint": {"lat": 53.42519, "lon": -2.32443}}, {"facility": "GSK Investigational Site", "city": "Sale", "state": "Cheshire", "zip": "M33 4BR", "country": "United Kingdom", "geoPoint": {"lat": 53.42519, "lon": -2.32443}}, {"facility": "GSK Investigational Site", "city": "Sale", "state": "Cheshire", "zip": "M33 7SS", "country": "United Kingdom", "geoPoint": {"lat": 53.42519, "lon": -2.32443}}, {"facility": "GSK Investigational Site", "city": "Stockport", "state": "Cheshire", "zip": "SK3 9NX", "country": "United Kingdom", "geoPoint": {"lat": 53.40979, "lon": -2.15761}}, {"facility": "GSK Investigational Site", "city": "Timperley", "state": "Cheshire", "zip": "WA15 7DD", "country": "United Kingdom", "geoPoint": {"lat": 53.4, "lon": -2.33333}}, {"facility": "GSK Investigational Site", "city": "Timperley", "state": "Cheshire", "zip": "WA15 7UN", "country": "United Kingdom", "geoPoint": {"lat": 53.4, "lon": -2.33333}}, {"facility": "GSK Investigational Site", "city": "Altrincham", "state": "Greater Manchester", "zip": "WA14 2DW", "country": "United Kingdom", "geoPoint": {"lat": 53.38752, "lon": -2.34848}}, {"facility": "GSK Investigational Site", "city": "Altrincham", "state": "Greater Manchester", "zip": "WA15 6PH", "country": "United Kingdom", "geoPoint": {"lat": 53.38752, "lon": -2.34848}}, {"facility": "GSK Investigational Site", "city": "Broadway, Davyhulme", "state": "Greater Manchester", "zip": "M41 7WJ", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Irlam, Manchester", "state": "Greater Manchester", "zip": "M44 5LH", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Irlam", "state": "Greater Manchester", "zip": "M44 5LH", "country": "United Kingdom", "geoPoint": {"lat": 53.44253, "lon": -2.42323}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M20 1EB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M20 2DN", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M20 2RN", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M20 3BG", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M20 4SS", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M20 6WF", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M22 4DH", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M22 5DW", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M22 5RB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M22 5RX", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M22 9UE", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M23 1JP", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M23 1JX", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M23 9AB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M27 9LB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M32 0DF", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M32 0PA", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M32 0RW", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M33 2TB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M33 3HF", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M33 4WB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M33 5JD", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M33 5PN", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M33 7SS", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M33 7XN", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M41 0NA", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M41 0SE", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M41 0TZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M41 5AA", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M41 7FN", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M41 7WJ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "M41 8AA", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "WA15 6BP", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "state": "Greater Manchester", "zip": "WA15 7UN", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Newall Green", "state": "Greater Manchester", "zip": "M23 2SY", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Northenden", "state": "Greater Manchester", "zip": "M22 4DH", "country": "United Kingdom", "geoPoint": {"lat": 53.40799, "lon": -2.25782}}, {"facility": "GSK Investigational Site", "city": "Northern Moor", "state": "Greater Manchester", "zip": "M23 0BX", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Pendlebury", "state": "Greater Manchester", "zip": "M27 8HP", "country": "United Kingdom", "geoPoint": {"lat": 53.51138, "lon": -2.32018}}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "state": "Greater Manchester", "zip": "M6 6ES", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "state": "Greater Manchester", "zip": "M7 4TP", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford", "state": "Greater Manchester", "zip": "M6 7HL", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "state": "Greater Manchester", "zip": "M7 1RD", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Stretford", "state": "Greater Manchester", "zip": "M32 9BD", "country": "United Kingdom", "geoPoint": {"lat": 53.45, "lon": -2.31667}}, {"facility": "GSK Investigational Site", "city": "Timperley", "state": "Greater Manchester", "zip": "WA15 6PH", "country": "United Kingdom", "geoPoint": {"lat": 53.4, "lon": -2.33333}}, {"facility": "GSK Investigational Site", "city": "Withington", "state": "Greater Manchester", "zip": "M20 1EY", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Wythenshawe", "state": "Greater Manchester", "zip": "M22 0EP", "country": "United Kingdom", "geoPoint": {"lat": 53.38027, "lon": -2.2654}}, {"facility": "GSK Investigational Site", "city": "Wythenshawe", "state": "Greater Manchester", "zip": "M22 5RN", "country": "United Kingdom", "geoPoint": {"lat": 53.38027, "lon": -2.2654}}, {"facility": "GSK Investigational Site", "city": "Wythenshawe", "state": "Greater Manchester", "zip": "M22 5RX", "country": "United Kingdom", "geoPoint": {"lat": 53.38027, "lon": -2.2654}}, {"facility": "GSK Investigational Site", "city": "Cadishead, Manchester", "zip": "M44 5DD", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Cheadle", "zip": "SK8 5BB", "country": "United Kingdom", "geoPoint": {"lat": 52.98333, "lon": -1.98333}}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 0EA", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 0EJ", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 0LS", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 0NU", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 0PF", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 0TU", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 7JW", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 7NA", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 8AR", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 8JA", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 8QD", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles, Manchester", "zip": "M30 9PS", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Eccles", "zip": "M30 0TU", "country": "United Kingdom", "geoPoint": {"lat": 53.48333, "lon": -2.33333}}, {"facility": "GSK Investigational Site", "city": "Ellenbrook, Manchester", "zip": "M28 1PB", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Irlam, Manchester", "zip": "M44 5LH", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Irlam, Manchester", "zip": "M44 6AJ", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Irlam, Manchester", "zip": "M44 6BL", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Irlam, Manchester", "zip": "M44 6FE", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Irlam, Manchester", "zip": "M44 6FN", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Irlam, Salford", "zip": "M44 6ZS", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Little Hulton, Manchester", "zip": "M28 0AY", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Little Hulton, Manchester", "zip": "M28 0BA", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Little Hulton, Manchester", "zip": "M38 9GR", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Little Hulton, Manchester", "zip": "M38 9LQ", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Little Hulton, Manchester", "zip": "M38 9RS", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Little Hulton, Manchester", "zip": "M38 9WX", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M16 0WL", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M20 4SS", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M22 4HD", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M22 4QN", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M22 9UH", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M23 1JX", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M23 9AB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M28 1PB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M32 0RN", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M32 8AQ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M32 9PA", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M33 3JS", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M33 4DX", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M33 7XZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M41 5BG", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M41 7AB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M41 7ZA", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M41 8GY", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M41 8TW", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M41 9FD", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M41 9NU", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M41 9SB", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "M7 4PF", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "WA14 1RH", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "WA14 4LJ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Manchester", "zip": "WA15 9SZ", "country": "United Kingdom", "geoPoint": {"lat": 53.48095, "lon": -2.23743}}, {"facility": "GSK Investigational Site", "city": "Pendlebury, Manchester", "zip": "M27 6EW", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M3 6AF", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M3 6BY", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M5 3TP", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M5 4QU", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M5 5HJ", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M5 5JR", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 5FX", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 5JA", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 5JS", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 5PH", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 5PW", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 5WN", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 5WW", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 7GU", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 7HL", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 8HA", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 8LE", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M6 8NR", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M7 1QE", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M7 1RD", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M7 1UD", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M7 3SE", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M7 4AE", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford, Manchester", "zip": "M7 4AS", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M5 3PH", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M5 4BS", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M6 3PH", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M6 5FX", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M6 5JG", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M6 5PP", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M6 5QQ", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M6 6ES", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M7 3SE", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Salford", "zip": "M7 4UF", "country": "United Kingdom", "geoPoint": {"lat": 53.48771, "lon": -2.29042}}, {"facility": "GSK Investigational Site", "city": "Stockport", "zip": "SK2 7EY", "country": "United Kingdom", "geoPoint": {"lat": 53.40979, "lon": -2.15761}}, {"facility": "GSK Investigational Site", "city": "Stockport", "zip": "SK3 9AD", "country": "United Kingdom", "geoPoint": {"lat": 53.40979, "lon": -2.15761}}, {"facility": "GSK Investigational Site", "city": "Stockport", "zip": "SK8 3JD", "country": "United Kingdom", "geoPoint": {"lat": 53.40979, "lon": -2.15761}}, {"facility": "GSK Investigational Site", "city": "Stockport", "zip": "SK8 3QA", "country": "United Kingdom", "geoPoint": {"lat": 53.40979, "lon": -2.15761}}, {"facility": "GSK Investigational Site", "city": "Stockport", "zip": "SK8 5LL", "country": "United Kingdom", "geoPoint": {"lat": 53.40979, "lon": -2.15761}}, {"facility": "GSK Investigational Site", "city": "Swinton, Manchester", "zip": "M27 0EW", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Swinton, Manchester", "zip": "M27 0NA", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Swinton, Manchester", "zip": "M27 4AF", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Swinton, Manchester", "zip": "M27 4BH", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Swinton", "zip": "M27 4BJ", "country": "United Kingdom", "geoPoint": {"lat": 53.5, "lon": -2.35}}, {"facility": "GSK Investigational Site", "city": "Swinton", "zip": "M27 8HP", "country": "United Kingdom", "geoPoint": {"lat": 53.5, "lon": -2.35}}, {"facility": "GSK Investigational Site", "city": "Walkden, Manchester", "zip": "M28 3AT", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Walkden, Manchester", "zip": "M28 3BT", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Walkden, Manchester", "zip": "M28 3DR", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Walkden, Manchester", "zip": "M28 3ZD", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Walkden, Manchester", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Worsley, Manchester", "zip": "M28 1FB", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Worsley, Manchester", "zip": "M28 1LZ", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Worsley, Manchester", "zip": "M28 3AT", "country": "United Kingdom"}, {"facility": "GSK Investigational Site", "city": "Wythenshawe", "zip": "M22 0LA", "country": "United Kingdom", "geoPoint": {"lat": 53.38027, "lon": -2.2654}}]}, "referencesModule": {"references": [{"pmid": "35131893", "type": "DERIVED", "citation": "Woodcock A, Janson C, Rees J, Frith L, Lofdahl M, Moore A, Hedberg M, Leather D. Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax. 2022 Dec;77(12):1187-1192. doi: 10.1136/thoraxjnl-2021-218088. Epub 2022 Feb 7."}, {"pmid": "32771685", "type": "DERIVED", "citation": "Kosinski M, Nelsen L, Rizio AA, Lay-Flurrie J, von Maltzahn R, Jacques L, Schatz M, Stanford RH, Svedsater H. Psychometric properties of the Asthma Control Test in 2 randomized clinical trials. J Allergy Clin Immunol Pract. 2021 Jan;9(1):561-563.e1. doi: 10.1016/j.jaip.2020.07.040. Epub 2020 Aug 6. No abstract available."}, {"pmid": "30053967", "type": "DERIVED", "citation": "Svedsater H, Jones R, Bosanquet N, Jacques L, Lay-Flurrie J, Leather DA, Vestbo J, Collier S, Woodcock A. Patient-reported outcomes with initiation of fluticasone furoate/vilanterol versus continuing usual care in the Asthma Salford Lung Study. Respir Med. 2018 Aug;141:198-206. doi: 10.1016/j.rmed.2018.06.003. Epub 2018 Jun 6."}, {"pmid": "29972089", "type": "DERIVED", "citation": "Jacques L, Bakerly ND, New JP, Svedsater H, Lay-Flurrie J, Leather DA. Effectiveness of fluticasone furoate/vilanterol versus fluticasone propionate/salmeterol on asthma control in the Salford Lung Study. J Asthma. 2019 Jul;56(7):748-757. doi: 10.1080/02770903.2018.1490751. Epub 2018 Oct 16."}, {"pmid": "28903864", "type": "DERIVED", "citation": "Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, Jacques L, Fletcher JL, Harvey C, Svedsater H, Leather D; Salford Lung Study Investigators. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017 Nov 18;390(10109):2247-2255. doi: 10.1016/S0140-6736(17)32397-8. Epub 2017 Sep 10. Erratum In: Lancet. 2017 Nov 18;390(10109):e40. Lancet. 2018 Feb 3;391(10119):430."}, {"pmid": "26651333", "type": "DERIVED", "citation": "Woodcock A, Bakerly ND, New JP, Gibson JM, Wu W, Vestbo J, Leather D. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthma. BMC Pulm Med. 2015 Dec 10;15:160. doi: 10.1186/s12890-015-0150-8."}, {"pmid": "24603195", "type": "DERIVED", "citation": "New JP, Bakerly ND, Leather D, Woodcock A. Obtaining real-world evidence: the Salford Lung Study. Thorax. 2014 Dec;69(12):1152-4. doi: 10.1136/thoraxjnl-2014-205259. Epub 2014 Mar 6. Erratum In: Thorax. 2015 Oct;70(10):1008."}], "seeAlsoLinks": [{"label": "IPD for this study will be made available via the Clinical Study Data Request site.", "url": "https://clinicalstudydatarequest.com"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "IPD for this study will be made available via the Clinical Study Data Request site.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR"], "timeFrame": "IPD is available via the Clinical Study Data Request site (click on the link provided below)", "accessCriteria": "Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.", "url": "https://clinicalstudydatarequest.com"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 4725 participants were screened of which 4233 participants were randomized to either initiate with FF/VI or continue their usual asthma maintenance therapy in a ratio of 1:1. The total duration of study was approximately 12 months (52 weeks).", "recruitmentDetails": "This was a multi-center, randomized, open label study to evaluate the effectiveness of fluticasone furoate (FF)/vilanterol (VI) Inhalation Powder (FF 100 micrograms \\[mcg\\]/VI 25 mcg or FF 200 mcg/VI 25 mcg) compared with usual asthma maintenance therapy in participants with asthma in a localized geographical region of United Kingdom.", "groups": [{"id": "FG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "FG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2119"}, {"groupId": "FG001", "numSubjects": "2114"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1946"}, {"groupId": "FG001", "numSubjects": "1920"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "173"}, {"groupId": "FG001", "numSubjects": "194"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}]}, {"type": "Other: Subject reached stopping criteria", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "97"}, {"groupId": "FG001", "numSubjects": "93"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "37"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "23"}, {"groupId": "FG001", "numSubjects": "31"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "BG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "2119"}, {"groupId": "BG001", "value": "2114"}, {"groupId": "BG002", "value": "4233"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49.7", "spread": "16.69"}, {"groupId": "BG001", "value": "49.9", "spread": "16.05"}, {"groupId": "BG002", "value": "49.8", "spread": "16.37"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1241"}, {"groupId": "BG001", "value": "1257"}, {"groupId": "BG002", "value": "2498"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "878"}, {"groupId": "BG001", "value": "857"}, {"groupId": "BG002", "value": "1735"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Count of Participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "65"}]}]}, {"title": "Asian - Central/South Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "35"}, {"groupId": "BG001", "value": "46"}, {"groupId": "BG002", "value": "81"}]}]}, {"title": "Asian - East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "13"}]}]}, {"title": "Asian - Japanese Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Asian - South East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "27"}]}]}, {"title": "Native Hawaiian or Other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "White - Arabic/North African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "11"}]}]}, {"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "2002"}, {"groupId": "BG001", "value": "1971"}, {"groupId": "BG002", "value": "3973"}]}]}, {"title": "Mixed race", "categories": [{"measurements": [{"groupId": "BG000", "value": "33"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "56"}]}]}, {"title": "Unknown", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The primary efficacy analysis (PEA) Population is defined as all Intent-to-Treat (ITT) participants (that is, all participants who were randomized and received at least one prescription of study medication) who have an ACT total score of \\<20 at Baseline (Day 0). The percentage of responders that is participants with an ACT total score \\>=20 or an increase from Baseline of \\>=3 has been presented", "populationDescription": "PEA Population. Only participants with non-missing ACT score were analyzed.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline (Day 0) and Week 24", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1399"}, {"groupId": "OG001", "value": "1373"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "71"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "The analysis method was logistic regression adjusted for randomized treatment, asthma maintenance therapy (AMT) at Baseline per randomization stratification, Baseline ACT total score, Baseline ACT total score squared, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "2.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.70", "ciUpperLimit": "2.34", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Have Either an ACT Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. ITT Population comprised of all participants who were randomized and received at least one prescription of study medication. The percentage of responders that is participants with an ACT total score \\>=20 or an increase from Baseline of \\>=3 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline (Day 0) and Weeks 12, 40 and 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"title": "Week 12, n=2032, 2009", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2032"}, {"groupId": "OG001", "value": "2009"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "62"}, {"groupId": "OG001", "value": "75"}]}]}, {"title": "Week 40, n=1938, 1904", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1938"}, {"groupId": "OG001", "value": "1904"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "71"}]}]}, {"title": "Week 52, n=1922, 1896", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1922"}, {"groupId": "OG001", "value": "1896"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "70"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "Logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, Baseline ACT total score squared, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.92", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.67", "ciUpperLimit": "2.20", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care for Week 12 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "Logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, Baseline ACT total score squared, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.45", "ciUpperLimit": "1.91", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care for Week 40 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "Logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, Baseline ACT total score squared, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.54", "ciUpperLimit": "2.02", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care for Week 52 has been presented."}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Asthma Control (ACT Total Score >=20) at Weeks 12, 24, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants with an ACT total score \\>=20 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Weeks 12, 24, 40 and 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"title": "Week 12, n=2032, 2009", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2032"}, {"groupId": "OG001", "value": "2009"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "61"}]}]}, {"title": "Week 24, n=1957, 1936", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1957"}, {"groupId": "OG001", "value": "1936"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "60"}]}]}, {"title": "Week 40, n=1938, 1904", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1938"}, {"groupId": "OG001", "value": "1904"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "58"}]}]}, {"title": "Week 52, n=1922, 1896", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1922"}, {"groupId": "OG001", "value": "1896"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "58"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "2.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.82", "ciUpperLimit": "2.40", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care at Week 12 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.96", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.70", "ciUpperLimit": "2.25", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care at Week 24 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.56", "ciUpperLimit": "2.06", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care at Week 40 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.69", "ciUpperLimit": "2.24", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care at Week 52 has been presented."}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Have an Increase From Baseline of >=3 in ACT Total Score at Weeks 12, 24, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants with an increase in ACT total score \\>=3 from Baseline has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline (Day 0) and Weeks 12, 24, 40 and 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"title": "Week 12, n=2032, 2009", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2032"}, {"groupId": "OG001", "value": "2009"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "55"}]}]}, {"title": "Week 24, n=1957, 1936", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1957"}, {"groupId": "OG001", "value": "1936"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "54"}]}]}, {"title": "Week 40, n=1938, 1904", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1938"}, {"groupId": "OG001", "value": "1904"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "53"}]}]}, {"title": "Week 52, n=1922, 1896", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1922"}, {"groupId": "OG001", "value": "1896"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "50"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "2.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.98", "ciUpperLimit": "2.62", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care at Week 12 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "2.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.81", "ciUpperLimit": "2.41", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care at Week 24 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.53", "ciUpperLimit": "2.02", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care at Week 40 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "The analysis method was logistic regression adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, gender and age.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.91", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.66", "ciUpperLimit": "2.21", "estimateComment": "Adjusted odds ratio comparing FF/VI with Usual Care at Week 52 has been presented."}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in ACT Total Score at Weeks 12, 24, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. Baseline value is the value at Visit 2 (Day 0) assessment. Change from Baseline is the value at post-dose visit minus Baseline. The least square mean change in ACT scores has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on ACT scale", "timeFrame": "Baseline (Day 0) and Weeks 12, 24, 40 and 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"title": "Week 12, n=2032, 2009", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2032"}, {"groupId": "OG001", "value": "2009"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.77", "spread": "0.087"}, {"groupId": "OG001", "value": "3.31", "spread": "0.087"}]}]}, {"title": "Week 24, n=1957, 1936", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1957"}, {"groupId": "OG001", "value": "1936"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.70", "spread": "0.093"}, {"groupId": "OG001", "value": "3.20", "spread": "0.094"}]}]}, {"title": "Week 40, n=1938, 1904", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1938"}, {"groupId": "OG001", "value": "1904"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.63", "spread": "0.096"}, {"groupId": "OG001", "value": "3.00", "spread": "0.097"}]}]}, {"title": "Week 52, n=1922, 1896", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1922"}, {"groupId": "OG001", "value": "1896"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.49", "spread": "0.094"}, {"groupId": "OG001", "value": "2.99", "spread": "0.095"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "MMRM adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, randomized treatment-by-Baseline ACT total score interaction, gender, age, visit and randomized treatment by visit interaction.", "statisticalMethod": "Mixed Model Repeated Measures (MMRM)", "paramType": "Mean Difference (Net)", "paramValue": "1.54", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.30", "ciUpperLimit": "1.77", "estimateComment": "Treatment difference of FF/VI versus Usual Care at Week 12 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "MMRM adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, randomized treatment-by-Baseline ACT total score interaction, gender, age, visit and randomized treatment by visit interaction.", "statisticalMethod": "MMRM", "paramType": "Mean Difference (Net)", "paramValue": "1.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.25", "ciUpperLimit": "1.76", "estimateComment": "Treatment difference of FF/VI versus Usual Care at Week 24 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "MMRM adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, randomized treatment-by-Baseline ACT total score interaction, gender, age, visit and randomized treatment by visit interaction.", "statisticalMethod": "MMRM", "paramType": "Mean Difference (Net)", "paramValue": "1.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.11", "ciUpperLimit": "1.63", "estimateComment": "Treatment difference of FF/VI versus Usual Care at Week 40 has been presented."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "MMRM adjusted for randomized treatment, AMT at Baseline per randomization stratification, Baseline ACT total score, randomized treatment-by-Baseline ACT total score interaction, gender, age, visit and randomized treatment by visit interaction.", "statisticalMethod": "MMRM", "paramType": "Mean Difference (Net)", "paramValue": "1.50", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.24", "ciUpperLimit": "1.76", "estimateComment": "Treatment difference of FF/VI versus Usual Care at Week 52 has been presented."}]}, {"type": "SECONDARY", "title": "Percentage of Participants in Each ACT Total Score Category (>=20, 16 to 19, <=15) at Weeks 12, 24, 40 and 52.", "description": "The ACT is a validated self-administered questionnaire utilizing 5 questions to assess asthma control during the past 4 weeks on a 5-point categorical scale (1 to 5). By answering all 5 questions, participants with asthma obtained an ACT score ranging between 5 and 25. Higher scores indicated better control of asthma. An ACT score of \\<=15 showed poorly controlled asthma; 16 to 19 showed partly controlled asthma and \\>=20 showed well controlled asthma. The total score was calculated as the sum of the scores from all 5 questions. The percentage of participants under each ACT total score category that is \\>=20, 16 to 19 and \\<=15 has been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in category title).", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Weeks 12, 24, 40 and 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"title": ">=20, Week 12, n=2032, 2009", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2032"}, {"groupId": "OG001", "value": "2009"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "61"}]}]}, {"title": "16 to 19, Week 12, n=2032, 2009", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2032"}, {"groupId": "OG001", "value": "2009"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "<=15, Week 12, n=2032, 2009", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2032"}, {"groupId": "OG001", "value": "2009"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "18"}]}]}, {"title": ">=20, Week 24, n=1957, 1936", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1957"}, {"groupId": "OG001", "value": "1936"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "60"}]}]}, {"title": "16 to 19, Week 24, n=1957, 1936", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1957"}, {"groupId": "OG001", "value": "1936"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "<=15, Week 24, n=1957, 1936", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1957"}, {"groupId": "OG001", "value": "1936"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": ">=20, Week 40, n=1938, 1904", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1938"}, {"groupId": "OG001", "value": "1904"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "58"}]}]}, {"title": "16 to 19, Week 40, n=1938, 1904", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1938"}, {"groupId": "OG001", "value": "1904"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "<=15, Week 40, n=1938, 1904", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1938"}, {"groupId": "OG001", "value": "1904"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": ">=20, Week 52, n=1922, 1896", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1922"}, {"groupId": "OG001", "value": "1896"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "58"}]}]}, {"title": "16 to 19, Week 52, n=1922, 1896", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1922"}, {"groupId": "OG001", "value": "1896"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "20"}]}]}, {"title": "<=15, Week 52, n=1922, 1896", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1922"}, {"groupId": "OG001", "value": "1896"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "30"}, {"groupId": "OG001", "value": "21"}]}]}]}, {"type": "SECONDARY", "title": "Annual Rate of Asthma-related Secondary Care Contacts", "description": "All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the National Health Service (NHS) as identified in the electronic medical records (EMR). Contacts were defined to be asthma-related if the most prominent signs and symptoms that the participant presented were a direct result of the participant's asthma. An asthma-related secondary care contact is defined as an inpatient admission or a specialist outpatient visit or an accident and emergency (A\\&E) contact. A participant with an A\\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. The least square mean annual rate of all asthma-related secondary care contacts along with 95% confidence interval has been presented.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Contacts per participant per year", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.30", "lowerLimit": "0.25", "upperLimit": "0.34"}, {"groupId": "OG001", "value": "0.30", "lowerLimit": "0.26", "upperLimit": "0.36"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.786", "pValueComment": "GLM assuming negative binomial distribution (NBD) adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age", "statisticalMethod": "Generalized Linear Model (GLM)", "paramType": "Ratio", "paramValue": "1.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.83", "ciUpperLimit": "1.28", "estimateComment": "Ratio comparing FF/VI with Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Annual Rate of Asthma-related Primary Care Contacts", "description": "All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the NHS as identified in the EMR. Contacts were defined to be asthma-related if the most prominent signs and symptoms that the participant presented were a direct result of the participant's asthma. Asthma-related primary care contacts is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional that can be considered as asthma-related as per Read codes. The least square mean annual rate of all asthma-related primary care contacts along with 95% confidence interval has been presented.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Contacts per participant per year", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.42", "lowerLimit": "1.36", "upperLimit": "1.47"}, {"groupId": "OG001", "value": "1.45", "lowerLimit": "1.39", "upperLimit": "1.51"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.461", "pValueComment": "GLM assuming NBD adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age", "statisticalMethod": "Generalized Linear Model (GLM)", "paramType": "Ratio", "paramValue": "1.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.97", "ciUpperLimit": "1.08", "estimateComment": "Ratio comparing FF/VI with Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Number of Participants With Time to First Asthma-related Primary Care Contact", "description": "Asthma-related primary care contact is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional that can be considered as asthma-related as per Read codes. Time to first asthma-related primary care contact was measured from the date of randomization (that is, study treatment start date) to the date of first asthma-related primary care contact, or study treatment stop date for participants who completed the study without any asthma-related primary care contacts (censored). Analyses of time to first asthma-related primary care contact was censored at Day 364. The number of participants at risk at Weeks 0, 13, 26, 39 and 52 has been presented. Kaplan Meier method of analysis was used. Study related primary care contacts (that is, contacts scheduled solely due to the participant taking part in clinical trial) were excluded from this analysis.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"title": "Week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}]}, {"title": "Week 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "1621"}, {"groupId": "OG001", "value": "1599"}]}]}, {"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "1208"}, {"groupId": "OG001", "value": "1214"}]}]}, {"title": "Week 39", "categories": [{"measurements": [{"groupId": "OG000", "value": "907"}, {"groupId": "OG001", "value": "932"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "479"}, {"groupId": "OG001", "value": "488"}]}]}]}, {"type": "SECONDARY", "title": "Annual Rate of All On-treatment Secondary Care Contacts", "description": "A secondary care contact is defined as an inpatient admission or a specialist outpatient visit or an A\\&E contact. A participant with an A\\&E contact and subsequent inpatient admission was considered to have had two healthcare contacts. The inpatient admissions recorded at two hospitals on the same day, were counted as a single (inpatient admission) secondary care contact. In the situation where inpatient admission periods overlapped (example, a new inpatient admission was recorded within the dates of an existing inpatient admission period), it was counted as a single (inpatient admission) healthcare contact with start date defined as the earliest inpatient admission date for either of the overlapping admissions and end date defined as the latest discharge date for either of the overlapping admissions. The least square mean annual rate of all on-treatment secondary care contacts along with 95% confidence interval has been summarized.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Contacts per participant per year", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.23", "lowerLimit": "4.91", "upperLimit": "5.57"}, {"groupId": "OG001", "value": "5.17", "lowerLimit": "4.86", "upperLimit": "5.51"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.822", "pValueComment": "GLM assuming NBD adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age", "statisticalMethod": "Generalized Linear Model (GLM)", "paramType": "Ratio", "paramValue": "0.99", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.91", "ciUpperLimit": "1.08", "estimateComment": "Ratio comparing FF/VI with Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Annual Rate of All On-treatment Primary Care Contacts", "description": "All contacts are defined as any encounter the participant may have with a doctor, nurse or other healthcare professionals working as part of the NHS as identified in the EMR. Total primary care contacts is defined as the sum of primary care contacts on a given calendar date with either a nurse, General Practitioner or other healthcare professional. The least square mean annual rate of all on-treatment primary care contacts along with 95% confidence interval has been presented.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Contacts per participant per year", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.61", "lowerLimit": "10.26", "upperLimit": "10.98"}, {"groupId": "OG001", "value": "11.64", "lowerLimit": "11.25", "upperLimit": "12.04"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "GLM assuming NBD adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age", "statisticalMethod": "Generalized Linear Model (GLM)", "paramType": "Ratio", "paramValue": "1.10", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.05", "ciUpperLimit": "1.15", "estimateComment": "Ratio comparing FF/VI with Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Number of Participants With Time to First Primary Care Contact", "description": "Time to first primary care contact is measured from the date of randomization (that is, study treatment start date) to the date of first primary care contact, or study treatment stop date for participants who completed the study without any primary care contacts (censored). Analyses of time to first primary care contact will be censored at Day 364. The number of participants at risk at Weeks 0, 13, 26, 39 and 52 has been presented. Kaplan Meier method of analysis was used. Study related primary care contacts (that is, contacts scheduled solely due to the participant taking part in clinical trial) were excluded from this analysis.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"title": "Week 0", "categories": [{"measurements": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}]}, {"title": "Week 13", "categories": [{"measurements": [{"groupId": "OG000", "value": "513"}, {"groupId": "OG001", "value": "483"}]}]}, {"title": "Week 26", "categories": [{"measurements": [{"groupId": "OG000", "value": "245"}, {"groupId": "OG001", "value": "242"}]}]}, {"title": "Week 39", "categories": [{"measurements": [{"groupId": "OG000", "value": "160"}, {"groupId": "OG001", "value": "178"}]}]}, {"title": "Week 52", "categories": [{"measurements": [{"groupId": "OG000", "value": "79"}, {"groupId": "OG001", "value": "96"}]}]}]}, {"type": "SECONDARY", "title": "Mean Annual Rate of Severe Asthma Exacerbations", "description": "A severe asthma exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) or antibiotics, and inpatient hospitalization, or emergency department visit due to asthma that required systemic corticosteroids or antibiotics. Least square mean for annual rate of severe asthma exacerbation along with 95% confidence interval has been presented.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Exacerbations per participant per year", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.41", "lowerLimit": "0.38", "upperLimit": "0.44"}, {"groupId": "OG001", "value": "0.40", "lowerLimit": "0.37", "upperLimit": "0.43"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.697", "pValueComment": "GLM assuming NBD adjusted for randomized treatment; asthma maintenance therapy and ACT total score at Baseline per randomization stratification; number of severe asthma exacerbations in previous year prior to randomization categorized; gender \\& age", "statisticalMethod": "Generalized Linear Model (GLM)", "paramType": "Ratio", "paramValue": "0.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.88", "ciUpperLimit": "1.09", "estimateComment": "Ratio comparing FF/VI with Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Time to First Severe Asthma Exacerbation.", "description": "A severe asthma exacerbation is defined as deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) or antibiotics, and inpatient hospitalization, or emergency department visit due to asthma that required systemic corticosteroids or antibiotics. The date of a severe asthma exacerbation was defined as the exacerbation onset date. Participants who completed the study without a severe asthma exacerbation were censored. Time to first severe asthma exacerbation was measured from the date of randomization (that is, study treatment start date) to the onset date of first severe asthma exacerbation, or study treatment stop date for participants who completed the study without any severe asthma exacerbations (censored). Analyses of time to first severe asthma exacerbation was censored at Day 364. The number of participants with severe asthma exacerbation has been presented.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "654"}, {"groupId": "OG001", "value": "634"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.504", "pValueComment": "Cox proportional hazards model with randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age as covariates", "statisticalMethod": "Cox proportional hazards model", "paramType": "Hazard Ratio (HR)", "paramValue": "0.96", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.86", "ciUpperLimit": "1.07", "estimateComment": "A hazard ratio \\<1 indicated a lower risk with FF/VI compared with Usual Care"}]}, {"type": "SECONDARY", "title": "Mean Number of Salbutamol Inhalers Prescribed for Each Participant Over the 12 Month Treatment Period.", "description": "Salbutamol was prescribed as a rescue medication to be used as and when necessary throughout the study. The number of salbutamol inhalers used by each participant during the study was calculated based on the total number of inhalers (adjusted to an equivalence of 200 metered actuations) prescribed. Number of salbutamol inhalers prescribed during the study was derived taking the participants time on study medication into account so it corresponds to 12 months on treatment. The least square mean number of salbutamol inhalers prescribed per participant during the study has been presented. Only participants exposed to study drug for at least 30 days were included in the analysis.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Mean number of inhalers per participant", "timeFrame": "Up to 12 months", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2116"}, {"groupId": "OG001", "value": "2108"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.0", "spread": "0.11"}, {"groupId": "OG001", "value": "7.2", "spread": "0.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "ANCOVA adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender,age \\& number of salbutamol inhalers in year prior to randomization", "statisticalMethod": "ANCOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.1", "ciUpperLimit": "-0.5", "estimateComment": "Difference of FF/VI versus Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Time to Modification of Initial Therapy", "description": "Initial therapy is defined as the treatment that the participant was prescribed at randomization. Modification of initial therapy included any change in brand, dose or frequency of inhaler, that is, stepping up in class, dose or frequency, stepping down in class, dose or frequency, switching to another brand of inhaler, switching treatment arm or withdrawal from the study. Time to modification of initial therapy was measured from the date of randomization (that is, exposure start date) to the date of modification of initial therapy or date of treatment termination for participants who completed the study without modifiying initial therapy (censored). The number of participants with modification of initial therapy has been presented.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "488"}, {"groupId": "OG001", "value": "563"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "Cox proportional hazards model with randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age as covariates", "statisticalMethod": "Cox proportional hazards model", "paramType": "Hazard Ratio (HR)", "paramValue": "1.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.09", "ciUpperLimit": "1.38", "estimateComment": "Hazard ratio for FF/VI versus Usual Care has been presented"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Have an Increase From Baseline of >=0.5 in Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] Total Score at Week 52.", "description": "The AQLQ(S) contained 32 items under the following four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items) and environmental stimuli (4 items). The response format consisted of a seven-point scale where a value of 1 indicated \"total impairment\" and a value of 7 indicated \"no impairment\". The total AQLQ(S) score is the mean of all 32 items in the questionnaire and each individual domain score was calculated as the mean of the items within that domain. Hence, the total and domain scores were each defined on a range from 1 to 7 with higher scores indicating a higher quality of life. Baseline value is the value at Day 0 assessment. Change from Baseline is post dose visit value minus Baseline. The percentage of responders that is, participants with an increase from Baseline of \\>=0.5 in AQLQ(S) total score has been presented. Only those participants available at the specified time point was analyzed.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline (Day 0) and Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1922"}, {"groupId": "OG001", "value": "1896"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "55"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "Logistic regression adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender, age and Baseline score.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.55", "ciUpperLimit": "2.06", "estimateComment": "Adjusted odds ratio of FF/VI with Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Have an Increase From Baseline of >=0.5 in AQLQ(S) Environmental Stimuli Domain Score at Week 52.", "description": "The AQLQ(S) contained 32 items under the following four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items) and environmental stimuli (4 items). The response format consisted of a seven-point scale where a value of 1 indicated \"total impairment\" and a value of 7 indicated \"no impairment\". The total environmental stimuli domain score was calculated as the mean of the items within the environmental stimuli domain. Hence, the environmental stimuli domain scores were each defined on a range from 1 to 7 with higher scores indicating a higher quality of life. Baseline value is the value at Day 0 assessment. Change from Baseline is post dose visit value minus Baseline. The percentage of responders that is, participants with an increase from Baseline of \\>=0.5 in AQLQ(S) environmental stimuli domain score has been presented. Only those participants available at the specified time point was analyzed.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline (Day 0) and Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1922"}, {"groupId": "OG001", "value": "1896"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "59"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "pValueComment": "Logistic regression adjusted for randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender, age and Baseline score.", "statisticalMethod": "Regression, Logistic", "paramType": "Adjusted Odds Ratio", "paramValue": "1.51", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.31", "ciUpperLimit": "1.73", "estimateComment": "Adjusted odds ratio of FF/VI versus Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Serious Adverse Event (SAE) of Pneumonia", "description": "A serious advent event (SAE) of pneumonia was defined as any SAE in the adverse event special interest (AESI) group of \"pneumonia\". The incidence of the SAEs of pneumonia for each treatment group is defined as the percentage of participants in that group who have experienced at least one SAE of pneumonia from start date of study treatment to the stop date of exposure + 28 days or date of study discontinuation, whichever is earliest. The percentage of participants with SAE of pneumonia has been presented.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY", "nonInferiorityComment": "Non-inferiority is demonstrated if the upper limit of the two-sided 95% confidence interval for the incidence ratio is less than 2.", "paramType": "Incidence ratio", "paramValue": "1.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.8", "ciUpperLimit": "2.7", "estimateComment": "Incidence ratio was calculated as percentage of participants who had at least one SAE of pneumonia in the FF/VI group divided by the percentage of participants who had at least one SAE of pneumonia in the Usual Care group."}]}, {"type": "SECONDARY", "title": "Time to First SAE of Pneumonia", "description": "An SAE of pneumonia was defined as any SAE in the AESI group of \"pneumonia\". The date of an event for an SAE of pneumonia was the AE onset date. Participants who do not have an SAE of pneumonia during the first 364 days of the treatment period (start date of exposure to min \\[end date of exposure + 28 days, date of study discontinuation, start date of exposure + 363\\]) were censored. Time to first SAE of pneumonia was measured from the date of randomization (that is, study treatment start date) to the onset date of first SAE of pneumonia. The number of participants with first on-treatment SAE of pneumonia has been presented.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "OTHER", "pValue": "0.255", "pValueComment": "Cox proportional hazards model with randomized treatment, asthma maintenance therapy at Baseline per randomization stratification, ACT total score at Baseline per randomization stratification, gender and age as covariates.", "statisticalMethod": "Cox proportional hazards model", "paramType": "Hazard Ratio (HR)", "paramValue": "1.45", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.77", "ciUpperLimit": "2.74", "estimateComment": "Hazard ratio for FF/VI versus Usual Care has been presented."}]}, {"type": "SECONDARY", "title": "Number of Participants With Fatal SAEs of Pneumonia", "description": "All SAEs included in the AESI group of \"pneumonia\" were considered as an SAE of pneumonia. Fatal SAEs of pneumonia are SAEs that led to death of participants. The number of participants with fatal SAEs of pneumonia has been presented.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With SAEs", "description": "An SAE is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect; important medical events which may require medical or surgical intervention for example, invasive or malignant cancers; all events of possible drug-induced liver injury with hyperbilirubinemia. The number of participants with on-treatment SAEs has been summarized.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "284"}, {"groupId": "OG001", "value": "284"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Drug Reactions (ADRs)", "description": "An ADR is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. ADRs are a subset of AEs for a given medicinal product.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 52", "groups": [{"id": "OG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers)."}, {"id": "OG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2119"}, {"groupId": "OG001", "value": "2114"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "326"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "On-treatment serious adverse events (SAEs) and non- serious adverse drug reactions (ADRs) were collected from the start of study treatment and until the follow up contact (Up to Week 52).", "description": "ITT Population comprised of all randomized participants who received at least one prescription of study medication", "eventGroups": [{"id": "EG000", "title": "Usual Care", "description": "Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers).", "deathsNumAffected": 27, "deathsNumAtRisk": 2119, "seriousNumAffected": 284, "seriousNumAtRisk": 2119, "otherNumAffected": 0, "otherNumAtRisk": 2119}, {"id": "EG001", "title": "FF/VI", "description": "Participants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler.", "deathsNumAffected": 15, "deathsNumAtRisk": 2114, "seriousNumAffected": 284, "seriousNumAtRisk": 2114, "otherNumAffected": 0, "otherNumAtRisk": 2114}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Anaemia of chronic disease", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Lymphadenopathy mediastinal", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Microcytic anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Pancytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Thrombocytopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 2114}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Arteriosclerosis coronary artery", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 14, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 2114}]}, {"term": "Atrioventricular block first degree", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Cardiac ventricular thrombosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Coronary artery thrombosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Diastolic dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hypertensive heart disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Left ventricular dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Left ventricular hypertrophy", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Myocarditis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Sinus bradycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Sinus node dysfunction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Tricuspid valve incompetence", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Ventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Branchial cyst", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Endocardial fibroelastosis", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Deafness", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Tinnitus", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Vertigo positional", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Adrenal insufficiency", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hyperparathyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Hyperthyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hypothyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Inappropriate antidiuretic hormone secretion", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Secondary hypogonadism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Angle closure glaucoma", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 2114}]}, {"term": "Conjunctivitis allergic", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Diabetic retinopathy", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Glaucoma", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 2114}]}, {"term": "Ocular hyperaemia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Retinal detachment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Abdominal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Abdominal wall haematoma", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Colitis ischaemic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Colitis ulcerative", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 2114}]}, {"term": "Diverticulum", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Duodenal ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Dysphagia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Gastrointestinal disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Haematemesis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Incarcerated umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Intestinal ischaemia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Large intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Proctalgia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Rectal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Umbilical hernia, obstructive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Generalised oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Multiple organ dysfunction syndrome", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Peripheral swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Surgical failure", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Bile duct stone", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Hepatic cirrhosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Hepatic failure", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Jaundice cholestatic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Mycotic allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Abdominal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Abdominal wall abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Atypical pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Bacteraemia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Biliary sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Bronchiolitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Candida infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Catheter site infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 11, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 8, "numAffected": 7, "numAtRisk": 2114}]}, {"term": "Chronic hepatitis C", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Empyema", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Encephalitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Genital herpes", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Genital infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Infected dermal cyst", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Infected skin ulcer", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Infective exacerbation of chronic obstructive airways disease", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Kidney infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Liver abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Localised infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Necrotising fasciitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Neutropenic sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Ophthalmic herpes simplex", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Pelvic inflammatory disease", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Periorbital cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Peritonsillar abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Pilonidal cyst", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 13, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 24, "numAffected": 23, "numAtRisk": 2114}]}, {"term": "Pneumonia mycoplasmal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Post procedural infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Post procedural sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Pseudomonas infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Sialoadenitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Staphylococcal infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Subcutaneous abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 13, "numAffected": 12, "numAtRisk": 2114}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Viral labyrinthitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Vulval abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 8, "numAffected": 8, "numAtRisk": 2114}]}, {"term": "Brain contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Burns third degree", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Cervical vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Comminuted fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Corneal abrasion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Craniocerebral injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Facial bones fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 2114}]}, {"term": "Femoral neck fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Fibula fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Foreign body", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Intentional overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Intentional product misuse", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Ligament rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Limb crushing injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Meniscus injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Pelvic fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Post procedural complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Post procedural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Post procedural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Pubis fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 2114}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Skull fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Skull fractured base", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Soft tissue injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Spinal fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Subdural haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Thermal burn", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Toxicity to various agents", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Ulna fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Wound secretion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Blood potassium decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Electrocardiogram QT prolonged", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "International normalised ratio abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Liver function test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 2114}]}, {"term": "Renal function test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Diabetic ketoacidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Electrolyte imbalance", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Glucose tolerance impaired", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hypercalcaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Hypokalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 2114}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Malnutrition", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Metabolic acidosis", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 13, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 12, "numAffected": 12, "numAtRisk": 2114}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 8, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Bursitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Fibromyalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Metatarsalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Osteopenia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Osteoporosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Palindromic rheumatism", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Polymyalgia rheumatica", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Rhabdomyolysis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Rheumatoid arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Acinic cell carcinoma of salivary gland", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Acute myeloid leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Adenoma benign", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "B-cell lymphoma recurrent", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 2114}]}, {"term": "Bladder cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Bladder transitional cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Brain cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Brain neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Breast cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Central nervous system lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Chondrosarcoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Colon cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Colorectal cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Endometrial adenocarcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Gastrointestinal carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Gastrointestinal stromal tumour", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hepatocellular carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Invasive ductal breast carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Lentigo maligna", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Lung cancer metastatic", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Malignant melanoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Malignant melanoma in situ", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Metastases to central nervous system", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Metastases to liver", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Metastases to lung", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Metastatic renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Oesophageal carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Penile squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Phyllodes tumour", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Precursor B-lymphoblastic lymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Renal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Renal cancer recurrent", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Renal neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Thyroid cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Ureteric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Amnesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Anosmia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Carpal tunnel syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Cerebrovascular disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Dementia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Drug withdrawal convulsions", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Haemorrhage intracranial", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Haemorrhagic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Multiple sclerosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Multiple sclerosis relapse", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Neuropathy peripheral", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Parkinson's disease", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Sensory disturbance", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Spinal cord compression", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Status epilepticus", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Subdural hygroma", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Trigeminal neuralgia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "VIth nerve paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Vascular dementia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Vertebral artery dissection", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Vocal cord paralysis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Abortion missed", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Unintended pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Unwanted pregnancy", "organSystem": "Pregnancy, puerperium and perinatal conditions", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Device dislocation", "organSystem": "Product Issues", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Alcohol withdrawal syndrome", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Alcoholism", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Antisocial personality disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Bipolar disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Confusional state", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Delusion", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Depressed mood", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 2114}]}, {"term": "Depression suicidal", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Eating disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hypomania", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Persistent depressive disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Post-traumatic stress disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Psychotic disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Schizoaffective disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 9, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 2114}]}, {"term": "Chronic kidney disease", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Haematuria", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Hydronephrosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Loin pain haematuria syndrome", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Ureteric obstruction", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Menorrhagia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Oedema genital", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Ovarian cyst torsion", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Pelvic pain", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Prostatitis", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Uterine haemorrhage", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 34, "numAffected": 30, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 30, "numAffected": 24, "numAtRisk": 2114}]}, {"term": "Atelectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Bronchiectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 5, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Emphysema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Interstitial lung disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Pharyngeal inflammation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Pickwickian syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Pleurisy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Pneumonia aspiration", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Pulmonary eosinophilia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Reflux laryngitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Respiratory arrest", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 2114}]}, {"term": "Sleep apnoea syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Decubitus ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 2114}]}, {"term": "Skin necrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Abortion induced", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Angiodysplasia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Aortic stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Circulatory collapse", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 6, "numAffected": 5, "numAtRisk": 2114}]}, {"term": "Essential hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Haematoma", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Raynaud's phenomenon", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}, {"term": "Superior vena cava occlusion", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 2114}]}, {"term": "Temporal arteritis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2119}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 2114}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Clinic visit", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}